The goal of this clinical trial is to evaluate the efficacy, safety, and pharmacodynamic characteristics of Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSCs) in adults with ischemic stroke in the anterior circulation during the recovery phase. Researchers will compare hUC-MSCs to a placebo to determine whether hUC-MSCs treatment is effective in treating recovery-phase anterior circulation ischemic stroke.

This study aims to further evaluate the efficacy and safety of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) in the treatment of stroke. Eligible participants will be randomized to receive either intravenous infusions of hUC-MSCs or a matching placebo. Over the 12-month study period, participants will be required to attend regular clinic visits for comprehensive neurological assessments, including the Fugl-Meyer Assessment (FMA), Modified Rankin Scale (mRS), National Institutes of Health Stroke Scale (NIHSS), Barthel Index (BI), and Mini-Mental State Examination (MMSE), as well as vascular imaging studies and biomarker analyses. Additionally, participants (or their caregivers, where applicable) will be instructed to consistently document neurological symptoms, functional activities, and the use of any rehabilitation medications or assistive devices.

Inclusion Criteria:

• Age ≥18 years and ≤70 years, regardless of gender.
• 14 to 90 days after ischemic stroke.
• Clinical diagnosis of anterior circulation ischemic stroke.
• National Institutes of Health Stroke Scale (NIHSS) score is 6-20 points (inclusive), with NIHSS motor arm (item 5) or motor leg (item 6) score of 2-4 points, and NIHSS level of consciousness item (1a) score <2 points.
• It was anticipated that participants would either be able to give informed consent or have a legal representative who could do so.

Exclusion Criteria:

• People who had a history of epilepsy, dementia, Parkinson's disease, severe depression, or other neurological or psychiatric disorders.
• Intracranial hemorrhagic conditions.
• Pre-stroke mRS score >1.
• Severe cardiovascular disease.
• Severe pulmonary diseases.

The general demographic data of participants, as well as clinical trial results including scoring data and safety data.

Individual Participant Data (IPD) is expected to be available upon trial completion on December 31, 2027, and this availability is anticipated to last until December 31, 2035.

Relevant personnel who have submitted an application and obtained approval and authorization from the investigator(s) and sponsor(s) will receive the subjects' demographic data, scoring data, and safety data-with such information to be provided and transmitted by the investigator(s) to the authorized personnel.